Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Average Recommendation of “Hold” by Analysts

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been given a consensus rating of “Hold” by the seven brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $62.1667.

A number of research firms recently commented on SUPN. Wall Street Zen cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th.

Institutional Trading of Supernus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in SUPN. Rubric Capital Management LP bought a new stake in Supernus Pharmaceuticals in the 2nd quarter worth approximately $21,908,000. Assenagon Asset Management S.A. bought a new stake in Supernus Pharmaceuticals in the 1st quarter worth approximately $27,428,000. Woodline Partners LP increased its stake in Supernus Pharmaceuticals by 63.5% in the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after acquiring an additional 490,835 shares during the last quarter. SG Americas Securities LLC increased its stake in Supernus Pharmaceuticals by 2,847.0% in the 1st quarter. SG Americas Securities LLC now owns 377,213 shares of the specialty pharmaceutical company’s stock worth $19,498,000 after acquiring an additional 364,413 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Supernus Pharmaceuticals by 67.1% in the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after acquiring an additional 338,584 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 0.6%

NASDAQ SUPN opened at $43.58 on Wednesday. The stock’s 50 day moving average is $48.41 and its 200 day moving average is $49.53. Supernus Pharmaceuticals has a 12 month low of $30.83 and a 12 month high of $59.68. The stock has a market cap of $2.53 billion, a PE ratio of -85.45, a P/E/G ratio of 0.94 and a beta of 0.55.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.